STOCKBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Updated 2026-06-07
Here’s whether Amgen Inc (AMGN) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Neutral.
🔵
Neutral
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); strong 1-year return of +21.8%. Concerns: 50-day MA is falling (-1.09% over 10 days); RSI 73 — overbought, elevated pullback risk; 3-month momentum negative (-7.3%). Currently 10.7% off its 52-week high. Score: +1/7.
AMGN is in a confirmed uptrend, trading above both its 50-day ($340.69) and 200-day ($329.36) moving averages. With an RSI of 72.9, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +21.8% compares to +24.4% for SPY (trailed the market by 2.6%).
$10,000 invested 1 year ago→ $12,176 today
vs. S&P 500 (SPY) — same period trailed market by 2.6%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($329.36)
✓Above 50-day MA ($340.69)
!RSI(14) neutral zone (30–70) — currently 72.9
✓Positive return (+21.8%)
!Within 10% of period high (−10.7%)
Period Range $349.58
$267.83$391.29
RSI (14) 72.9
0 · OversoldOverbought · 100
Key Metrics
Price$349.58
Period Return+21.8%
Period High$391.29
Period Low$267.83
Drawdown−10.7%
MA-50$340.69
MA-200$329.36
RSI (14)72.9
Avg Volume (30d)2.6M
vs. SPYtrailed by 2.6%
Return Rank#524 of 1245
Trend Signals
Price is above the 200-day moving average ($329.36)
Price is above the 50-day moving average ($340.69)